LONDON, UK, 20 December 2007 - SkyePharma PLC (LSE: SKP) today announces it has revised the agreement with Abbott for the development and commercialization in the United States of FlutiformTM, the Company’s product under development for the treatment of asthma. Under the terms of the amended agreement, Abbott assumes the responsibility and costs for additional clinical work required and agreed upon by the U.S. Food and Drug Administration (FDA) and submitting the New Drug Application (NDA) for Flutiform.
